- Home
- SYBT vs KNSA Comparison
SYBT vs KNSA Comparison
Compare SYBT & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBT
- KNSA
- Stock Information
- Founded
- SYBT 1904
- KNSA 2015
- Country
- SYBT United States
- KNSA United Kingdom
- Employees
- SYBT N/A
- KNSA N/A
- Industry
- SYBT Major Banks
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- SYBT Finance
- KNSA Health Care
- Exchange
- SYBT Nasdaq
- KNSA Nasdaq
- Market Cap
- SYBT 2.2B
- KNSA 2.1B
- IPO Year
- SYBT N/A
- KNSA 2018
- Fundamental
- Price
- SYBT $79.47
- KNSA $28.80
- Analyst Decision
- SYBT Hold
- KNSA Strong Buy
- Analyst Count
- SYBT 3
- KNSA 6
- Target Price
- SYBT $80.33
- KNSA $39.33
- AVG Volume (30 Days)
- SYBT 154.6K
- KNSA 1.0M
- Earning Date
- SYBT 07-23-2025
- KNSA 07-22-2025
- Dividend Yield
- SYBT 1.56%
- KNSA N/A
- EPS Growth
- SYBT 16.29
- KNSA N/A
- EPS
- SYBT 4.14
- KNSA N/A
- Revenue
- SYBT $353,277,000.00
- KNSA $481,166,000.00
- Revenue This Year
- SYBT $14.39
- KNSA $37.21
- Revenue Next Year
- SYBT $5.04
- KNSA $5.32
- P/E Ratio
- SYBT $19.14
- KNSA N/A
- Revenue Growth
- SYBT 8.97
- KNSA 59.45
- 52 Week Low
- SYBT $52.30
- KNSA $17.82
- 52 Week High
- SYBT $83.67
- KNSA $30.69
- Technical
- Relative Strength Index (RSI)
- SYBT 55.71
- KNSA 55.46
- Support Level
- SYBT $81.22
- KNSA $27.92
- Resistance Level
- SYBT $83.67
- KNSA $29.25
- Average True Range (ATR)
- SYBT 1.83
- KNSA 0.96
- MACD
- SYBT -0.13
- KNSA -0.02
- Stochastic Oscillator
- SYBT 44.00
- KNSA 80.93
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.